@article{6d908d034f3b42189a59680ee4720d9d,
title = "Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and Accelerate Nucleotide Exchange",
abstract = "The success of targeted covalent inhibitors in the global pharmaceutical industry has led to a resurgence of covalent drug discovery. However, covalent inhibitor design for flexible binding sites remains a difficult task due to a lack of methodological development. Here, we compared covalent docking to empirical electrophile screening against the highly dynamic target K-Ras(G12C). While the overall hit rate of both methods was comparable, we were able to rapidly progress a docking hit to a potent irreversible covalent binder that modifies the inactive, GDP-bound state of K-Ras(G12C). Hydrogen-deuterium exchange mass spectrometry was used to probe the protein dynamics of compound binding to the switch-II pocket and subsequent destabilization of the nucleotide-binding region. SOS-mediated nucleotide exchange assays showed that, contrary to prior switch-II pocket inhibitors, these new compounds appear to accelerate nucleotide exchange. This study highlights the efficiency of covalent docking as a tool for the discovery of chemically novel hits against challenging targets.",
author = "Nnadi, \{Chimno I.\} and Jenkins, \{Meredith L.\} and Gentile, \{Daniel R.\} and Bateman, \{Leslie A.\} and Daniel Zaidman and Balius, \{Trent E.\} and Nomura, \{Daniel K.\} and Burke, \{John E.\} and Shokat, \{Kevan M.\} and Nir London",
note = "Author Contributions C.I.N., N.L., and K.M.S. designed the study and wrote the manuscript with input from all authors. N.L. and D.Z. performed docking and computational analysis. C.I.N. and T.E.B. performed cheminformatics analysis. C.I.N., N.L., D.R.G., and L.A.B. synthesized small molecules for the initial screens. C.I.N. expressed and purified the protein and performed biochemical X-ray crystallography, and synthesized compounds for structure-activity relationships. M.L.J. and J.E.B. performed HDX-MS structural studies and analysis. D.Z. analyzed HRMS results. C.I.N., N.L., K.M.S. performed analysis of all biochemical results. Funding This work is supported by a National Institutes of Health Grant R01 (5R01CA190408) to K.M.S. and a F30 Kirschstein-NRSA (1F30CA214015) to C.I.N. This research was also supported by a Stand Up To Cancer−American Cancer Society Lung Cancer Dream Team Translational Research Grant to K.M.S. (SU2C-AACR-DT17-15). Stand Up to Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. N.L. is the incumbent of the Alan and Laraine Fischer Career Development Chair. N.L. would like to acknowledge funding from the Israel Science Foundation (grant No. 1097/16), the Rising Tide Foundation, and a research career development award from the Israel Cancer Research Foundation. J.E.B. would like to acknowledge funding from the CIHR new investigator program as well as a discovery research grant from the Natural Sciences and Engineering Research Council of Canada (NSERC-2014-05218). D.K.N. would like to acknowledge funding from a National Institutes of Health Grant (5R01CA172667). Notes The authors declare the following competing financial interest(s): K.M.S. is an inventor on UCSF patents related to K-Ras (G12C) inhibitors licensed to Wellspring Biosciences. K.M.S. is a stockholder and consultant to Wellspring Biosciences.",
year = "2018",
month = feb,
day = "26",
doi = "10.1021/acs.jcim.7b00399",
language = "الإنجليزيّة",
volume = "58",
pages = "464--471",
journal = "Journal of Chemical Information and Modeling",
issn = "1549-9596",
publisher = "American Chemical Society",
number = "2",
}